Research map: Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series

Back to the article

Papers in this map

  1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  2. Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study · 2026 · Related
  3. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  4. Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital · 2026 · Related
  5. Exploring the next generation of antibody–drug conjugates · Kyoji Tsuchikama · 2024 · 632 citations · Cited by this paper
  6. Magnetic Resonance-Guided Radiotherapy for Unresectable Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Series and Review of Treatment Options · 2026 · Related
  7. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma · Thomas B. Powles · 2024 · 184 citations · Cited by this paper
  8. Hyperbaric Oxygen Therapy for Late Radiation-Induced Duodenal Toxicity After Stereotactic Body Radiotherapy in a Patient with Cholangiocellular Carcinoma: A Unique Case Report · 2026 · Related
  9. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials · Xinan Sheng · 2023 · 180 citations · Cited by this paper
  10. Older Age Does Not Have an Impact on Postoperative Complication Risk Following Transurethral Resection of the Bladder Tumor · 2026 · Related
  11. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study · Bob T. Li · 2024 · 118 citations · Cited by this paper
  12. ESR1 Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report · 2026 · Related
  13. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma · Bradley Alexander McGregor · 2023 · 96 citations · Cited by this paper
  14. Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives · 2026 · Related
  15. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer · Xinan Sheng · 2025 · 95 citations · Cited by this paper
  16. The Efficacy of Transcutaneous Electrical Acupoint Stimulation as an Adjunct to Standard Bladder Training for Bladder Emptying After Radical Hysterectomy for Cervical Cancer: A Randomized Controlled Trial · 2026 · Related
  17. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives · Giorgio Patelli · 2022 · 94 citations · Cited by this paper
  18. Response to Zona, E.E.; Israel, J.S. Toward Individualized Management: A Commentary on Perioperative Systemic Therapy Guidelines in Breast Cancer Surgery and Reconstruction. Comment on “Galuia et al. Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations. Curr. Oncol. 2025, 32, 154” · 2026 · Related
  19. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial · Thomas B. Powles · 2025 · 93 citations · Cited by this paper
  20. Using Q-Methodology to Identify Core Illness Experience Dimensions in Treated Lymphoma Patients · 2026 · Related
  21. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study · Li Qun Zhou · 2024 · 63 citations · Cited by this paper
  22. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial · Masataka Yagisawa · 2024 · 42 citations · Cited by this paper
  23. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study · J. Zhang · 2025 · 32 citations · Cited by this paper
  24. Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma · Vadim S. Koshkin · 2025 · 12 citations · Cited by this paper
  25. Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges · Fanhao Zeng · 2025 · 5 citations · Cited by this paper
  26. Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors · Y. Zhu · 2025 · 5 citations · Cited by this paper
  27. Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02). · K. Jung · 2026 · 3 citations · Cited by this paper
  28. Untitled · Cited by this paper

Source: OpenAlex (CC0)